$1100 | SAVE $150 | Single User
$2200 | SAVE $300 | Site License
$3520 | SAVE $480 | Enterprise License

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017
[Report Updated: 01-09-2017]

Published by Delve Insight: 01 Sep 2017 | 118004 | In Stock

Introduction

DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor-Mechanism of action Insights, 2017”, report provides comprehensive insights of the ongoing therapeutic research and development across Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight`s team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope of the report

• The report provides a snapshot of the pipeline development for the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor

• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor

• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information

• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor

• The report also covers the dormant and discontinued pipeline projects related to the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor

Reasons to Buy

• Establish comprehensive understanding of the pipeline activity across this Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor to formulate effective R&D strategies

• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor therapeutics

• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Table of Contents
for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017 [Report Updated: 01-09-2017]

  • 1. Report Introduction

    2. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Overview

    3. Pipeline Therapeutics

    • An Overview of Pipeline Products for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor

    4. Comparative Analysis

    5. Products in Clinical Stage

    5.1 Drug Name : Company Name

    • Product Description

    • Research and Development

    • Product Development Activities

    6. Products in Pre-Clinical and Discovery Stage

    6.1 Drug Name : Company Name

    • Product Description

    • Research and Development

    • Product Development Activities

    7. Therapeutic Assessment

    • Assessment by Route of Administration

    • Assessment by Stage and Route of Administration

    • Assessment by Molecule Type

    • Assessment by Stage and Molecule Type

    8. Inactive Products

    8.1 Drug Name : Company Name

    • Product Description

    • Research and Development

    • Product Development Activities

    Appendix

    Report Methodology

    Consulting Services

    Disclaimer

    About DelveInsight

List Of Tables
in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017 [Report Updated: 01-09-2017]

Table 1:Total Products for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor

Table 2: Products in Clinical Stage

Table 3: Products in Pre-Clinical and Discovery Stage

Table 4: Assessment by Route of Administration

Table 5: Assessment by Stage and Route of Administration

Table 6: Assessment by Molecule Type

Table 7: Assessment by Stage and Molecule Type

Table 8: Inactive Products

List Of Figures, Charts and Diagrams
in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017 [Report Updated: 01-09-2017]

Figure 1:Total Products for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor

Figure 2: Products in Clinical Stage

Figure 3: Products in Pre-Clinical and Discovery Stage

Figure 4: Assessment by Route of Administration

Figure 5: Assessment by Stage and Route of Administration

Figure 6: Assessment by Molecule Type

Figure 7: Assessment by Stage and Molecule Type

Figure 8: Inactive Products

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

118004 | DIMA0356

Number of Pages

60

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2018
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
23 Oct 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
24 Apr 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insight, 2018
“Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2018” report by...
14 Feb 2018 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2017
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
10 Oct 2017 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors-Pipeline Insights,...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017 [Report Updated: 01-09-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...